Edition:
Deutschland

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

107.85USD
18:52 Uhr
Change (% chg)

$-0.62 (-0.57%)
Prev Close
$108.47
Open
$108.38
Day's High
$109.14
Day's Low
$107.82
Volume
146,358
Avg. Vol
993,862
52-wk High
$127.57
52-wk Low
$73.54

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical... (more)

Buy/Sell

Sell Hold Buy
2.13 Mean rating from 23 analysts

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

Alexion pays $21 mln resolving charges of breaking U.S. foreign corruption law -SEC

WASHINGTON, July 2 Alexion Pharmaceuticals has agreed to pay $21 million to resolve U.S. charges that it violated a major anti-corruption law when two of its subsidiaries paid Turkish and Russian officials for favorable treatment of its Soliris drug, the top securities regulator said on Thursday.

BRIEF-Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission

* ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Alexion Announces Phase 3 Study Of Weekly Subcutaneous Ultomiris Met Primary Endpoint

* ALEXION ANNOUNCES PHASE 3 STUDY OF WEEKLY SUBCUTANEOUS ULTOMIRIS® (RAVULIZUMAB-CWVZ) MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

Activist investor Elliott pushes Alexion Pharma to sell itself

Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

UPDATE 2-Activist investor Elliott pushes Alexion Pharma to sell itself

May 12 Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.

Elliott again pushes Alexion Pharma to explore a sale

May 12 Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.

BRIEF-Elliott Advisors Sends Letter To Alexion Pharmaceuticals

* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE

U.S. RESEARCH ROUNDUP-Ashland Global Holdings, Lyft, Solaredge Technologies

May 7 Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight * Lyft Inc : Piper Sandler cuts to neutral from overweight * Natera Inc : JP Morgan raises to overweight from neutral * Occidental Petroleum Corp

BRIEF-Alexion Pharmaceuticals Sees FY Revenue $5,230 Mln To $5,330 Mln

* Q1 REVENUE $1.445 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.36 BILLION

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.78%
Rohstoffe +0.42%
Industrie +0.49%
Konjunktur abhängige Waren & Dienstleistungen +1.00%
Konjunktur unabhängige Waren & Dienstleistungen +1.41%
Finanzindustrie -0.51%
Pharma -0.30%
Technologie +0.78%
Telekommunikation +1.52%